CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.

MLA

Gutierrez, J.Antonio, et al. “CYP2C19 Status and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: Insights from the EUCLID Trial.” American Heart Journal, vol. 229, Nov. 2020, pp. 118–20. EBSCOhost, https://doi.org/10.1016/j.ahj.2020.07.017.

APA

Gutierrez, J. A., Heizer, G. M., Jones, W. S., Rockhold, F. W., Mahaffey, K. W., Fowkes, F. G. R., Berger, J. S., Baumgartner, I., Held, P., Katona, B. G., Norgren, L., Blomster, J. I., Hiatt, W. R., & Patel, M. R. (2020). CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. American Heart Journal, 229, 118–120. https://doi.org/10.1016/j.ahj.2020.07.017

Chicago

Gutierrez, J. Antonio, Gretchen M. Heizer, W. Schuyler Jones, Frank W. Rockhold, Kenneth W. Mahaffey, F. Gerry R. Fowkes, Jeffrey S. Berger, et al. 2020. “CYP2C19 Status and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: Insights from the EUCLID Trial.” American Heart Journal 229 (November): 118–20. doi:10.1016/j.ahj.2020.07.017.